Application of generative artificial intelligence to utilize unstructured clinical data for acceleration of
Alex Z Kadhim1, Zachary Green2, Iman Nazari3
1Department of Human Genetics and Genomic Medicine, University of Southampton, Southampton SO16 6YD, UK; National Institute for Health Research (NIHR) Southampton Biomedical Research Centre, Southampton SO16 6YD, UK.
Background:
Inflammatory bowel disease (IBD) research is a dynamic field. However, the growing volume of electronic health records (EHRs) and research data presents significant challenges. Traditional methods for structuring unstructured EHRs are labor-intensive and lack scalability. Large language models (LLMs) may present a solution, however, their usefulness in data standardization in the context of IBD remains unknown. We sought to evaluate LLMs in structuring free-text histology and radiology reports from IBD patients (n = 32,041), compare their performance to manual clinician curation, and assess the usefulness of fine-tuning and retrieval-augmented generation (RAG).
Methods:
We developed an IBD-specialized LLM-based framework utilizing structured prompt engineering and fine-tuning. Free-text reports from two independent sites were manually curated and processed using various LLMs (n = 120).
Findings:
Overall, Llama 3.3 achieved the highest F1 scores for histology and imaging (1.00 ± 0 and 0.85 ± 0.29, respectively) in extracting findings and anatomical regions, surpassing other models in structured data generation. Fine-tuning improved the performance of the smaller Llama 3.1 8B model for imaging reports (0.70 ± 0.46 vs. 0.82 ± 0.35), enabling better extraction with reduced computational requirements.
Conclusions:
Our findings demonstrate the feasibility of LLM-based automated structuring of IBD-related medical records. Unstructured data from free-text reports can be reliably converted into standardized ontologies with location, severity, and qualifiers. These advancements enable scalable, privacy-compliant AI-driven solutions for data standardization.
Funding:
The Institute for Life Sciences, University of Southampton, the NIHR Southampton BRC, and EPSRC (EP/Y01720X/1).
More Related Videos
09:08Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies
Published on: June 2, 2021
07:10Author Spotlight: Development and Application of a Canine IBD Gut-on-a-Chip Model for 3D Intestinal Morphogenesis Studies
Published on: February 9, 2024
Related Concept Videos
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD:
